Enter inventor name

Michael Schriewer

This inventor holds 35 USPTO granted patents, plus 1 CIPO patent, primarily in Antibacterial Compounds. Top assignee: Bayer Aktiengesellschaft. Active years: 1987-1998.

USPTO Granted Patents = 35

% Patents Active = 100.0

CIPO Patents = 1

Average Co-Inventor Count = 4.6

ph-index = 11

Forward Citations = 408(Granted Patents)

Location History:

Leverkusen, DE (1987 - 1990)
Bayerwerk, DE (1991)
Odenthal, DE (1988 - 1998)

Company Filing History:

35 out of 12,223

Bayer Aktiengesellschaft

patents

Years Active: 1987-1998

Loading Chart...

Areas of Expertise:

Antibacterial

Quinolone Derivatives

Carboxylic Acids

Naphthyridone

Enantiomerically Pure

5-Alkylquinolone

Benzoic Acid

Pyridine-Enamines

1,8-Bridged

Active Intermediates

Pharmaceutical Chemistry

Drug Development

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5723627 - Preparation of 7-(3-amino- and (1998-03-03),

2. 5648493 - Preparation of 7-(3-amino- and (1997-07-15),

3. 5607942 - 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid (1997-03-04),

4. 5457104 - Quinolone- and naphthyridonecarboxylic acid derivatives (1995-10-10),

5. 5453422 - Quinolone- and naphthyridone carboxylic acid derivatives, process for (1995-09-26),

6. 5416096 - 7-(1-pyrrolidinyl)-3-quinolone carboxylic acid derivatives as (1995-05-16),

7. 5284855 - 7-(2,7-diazabicyclo[3.3.0]octyl)-3-quinolone-and-naphthyridonecarboxylic (1994-02-08),

8. 5284842 - Quinolone- and naphthridone carboxylic acid derivatives, process for (1994-02-08),

9. 5252734 - Antibacterial 5-alkylquinolonecarboxylic acids (1993-10-12),

10. 5237060 - Process of preparing enantiomerically pure 1,8-bridged (1993-08-17),

11. 5202337 - 7-(2,7-diazabicyclo[3.3.0]octyl)-3-quinoline- and (1993-04-13),

12. 5190955 - Antibacterial (1993-03-02),

13. 5173484 - Quinolone- and naphthyridone carboxylic acid derivatives, process for (1992-12-22),

14. 5140033 - Antibacterial 5-alkylquinolonecarboxylic acids (1992-08-18),

15. 5061712 - Preparation of 7-(3-amino- and (1991-10-29),

Title: The Innovative Contributions of Michael Schriewer

Introduction

Michael Schriewer, an accomplished inventor based in Odenthal, Germany, has made significant strides in the field of antibacterial compounds. With a remarkable portfolio consisting of 35 patents, he has established himself as a key figure in pharmaceutical research and development.

Latest Patents

Among his latest innovations, Schriewer has focused on the preparation of antibacterial compounds. His patents describe intricate methods that involve condensing various oxo and amino compounds to create new, effective antibacterial agents. His expertise in synthesizing these compounds allows for advancements in medical treatments, demonstrating his commitment to improving health outcomes.

Career Highlights

Schriewer is affiliated with Bayer Aktiengesellschaft, a leading company known for its innovative pharmaceutical products. Throughout his career, he has successfully contributed to numerous projects focused on developing new therapies and improving existing pharmaceutical formulations. His extensive knowledge and skill have led to breakthroughs in the field of medicinal chemistry.

Collaborations

During his time at Bayer, Schriewer has collaborated with other esteemed professionals in the industry, including Klaus Grohe and Karl G Metzger. These partnerships have facilitated the exchange of ideas and expertise, enhancing the quality of his research and leading to the development of cutting-edge solutions in antibacterial treatments.

Conclusion

In conclusion, Michael Schriewer's contributions to the field of antibiotic research are noteworthy. His dedication to innovation and collaboration has resulted in numerous patents that continue to impact the medical community. With a strong foundation in science and a commitment to improving human health, Schriewer exemplifies the spirit of modern invention in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]